Novonesis (Novozymes) A/S
- Industry
- Biotechnology & Enzymes
- Exchange
- CO
- Country
- Denmark
- Employees
- 10,933
- Website
- www.novonesis.com
Composite valuation range · conservative 255–300 / fair 320–390 / optimistic 415–510. At 366.3, Within the fair intrinsic-value range.
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
History
Novonesis A/S was formed on 28 January 2024 through the merger of two Danish listed companies, Novozymes A/S (the global leader in industrial enzymes) and Chr. Hansen Holding A/S (the global leader in probiotics), creating a biotechnology platform headquartered in Bagsvaerd outside Copenhagen and listed on Nasdaq Copenhagen (NSIS-B B-shares as the main traded class, NSIS-A A-shares held by Novo Holdings). The merger, led by Novo Holdings and valued at around EUR 12 billion, lifted net debt to EBITDA from roughly 1.0x to 2.3x for the integration period. Post-merger integration progressed faster than planned: cost synergies reached a 100% run rate a year ahead of schedule (confirmed in a management release in September 2024, with the 100% target achieved in the second half of 2025 versus an original plan of the second half of 2026), and the adjusted EBITDA margin rose from about 35% to 37.1% while net debt to EBITDA fell back to 1.9x. By FY2025, the first full year after the merger, the combined company generated revenue of DKK 32,376M / USD 4,701M (+7% organic), structured into two divisions: Food & Health Biosolutions (probiotics, food enzymes and microbiome solutions, +8% organic) and Planetary Health Biosolutions (industrial enzymes, feed and agricultural biology, +6% organic). In the first half of 2026 Novonesis closed a USD 1.79 billion acquisition of the dsm-firmenich Feed Enzyme Alliance, which raised its feed enzyme share from roughly 40% to about 50%.
Industry position
Novonesis is the global leader in both of its core sub-segments, holding an estimated 48% share of the worldwide industrial enzyme market (versus DSM-Firmenich at about 18% and AB Enzymes at about 10%) and roughly 35% of the global probiotics market (versus IFF at about 25% and DSM-Firmenich at about 15%). Its scale is reflected in FY2025 adjusted gross margin of 59.1% and an adjusted EBITDA margin of 37.1%, the highest among the industrial-enzyme, probiotics and food-ingredient peers it is compared against (Givaudan 24.2%, Symrise around 21.5%, IFF around 19%, dsm-firmenich around 17%). The company derives its competitive position from several factors documented in the source: very high customer switching costs, since a strain or enzyme formulation written into a customer's product requires re-validation and regulatory filing taking one to two years and supports long supply contracts of five to fifteen years; a library of more than 750 microbial strains plus over 6,000 patents and sustained R&D spending of about 14% of revenue; a globally distributed network of more than 30 production facilities across Denmark, the United States, Brazil, China, India, Ireland, Greece and Finland serving over 60 countries; and the backing of strategic shareholder Novo Holdings A/S (25.5% economic interest, 63.35% of votes), which supplies long-term capital and R&D and M&A support. It is fully focused on biosolutions, unlike more diversified peers such as IFF and dsm-firmenich, and its serviceable market is estimated at around USD 25-30 billion. Its main competitors include dsm-firmenich and AB Enzymes in industrial enzymes and IFF and dsm-firmenich in probiotics.